Systemic Delivery of Extracellular Vesicles Attenuates Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction
Atrial Fibrillation - Biological Therapies
Atrial fibrillation (AF) is a common comorbidity in heart failure with preserved ejection fraction (HFpEF) patients. To date, treatments for HFpEF-related AF have been limited to anti-arrhythmic drugs and ablation. Here we examined the effects of immortalized cardiosphere-derived extracellular vesicles (imCDCevs) in rats with HFpEF.
This study sought to investigate the mechanisms of AF in HFpEF and probe the potential therapeutic efficacy of imCDCevs in HFpEF-related AF.
Dahl salt-sensitive rats were fed a high-salt diet for 7 weeks to induce HFpEF and randomized to receive imCDCevs (n = 18) or vehicle intravenously (n = 14). Rats fed a normal-salt diet were used as control animals (n = 26). A comprehensive characterization of atrial remodeling was conducted using functional and molecular techniques.
HFpEF-verified animals showed significantly higher AF inducibility (84%) compared with control animals (15%). These changes were associated with prolonged action potential duration, slowed conduction velocity (connexin 43 lateralization), and fibrotic remodeling in the left atrium of HFpEF compared with control animals. ImCDCevs reversed adverse electrical remodeling (restoration of action potential duration to control levels and reorganization of connexin 43) and reduced AF inducibility (33%). In addition, fibrosis, inflammation, and oxidative stress, which are major pathological AF drivers, were markedly attenuated in imCDCevs-treated animals. Importantly, these effects occurred without changes in blood pressure and diastolic function.
Thus, imCDCevs attenuated adverse remodeling, and prevented AF in a rat model of HFpEF.
1. "Trends in prevalence and outcome of heart failure with preserved ejection fraction". N Engl J Med . 2006;355:251-259.
2. "Epidemiology of heart failure with preserved ejection fraction". Nat Rev Cardiol . 2017;14:591-602.
3. "Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction". PLoS One . 2021;16:e0254641.
4. "Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial". Circulation . 2010;121:1393-1405.
5. "Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study". Circulation . 2013;128:1085-1093.
6. "Heart failure with preserved ejection fraction in perspective". Circ Res . 2019;124:1598-1617.
7. "The secret life of exosomes: what bees can teach us about next-generation therapeutics". J Am Coll Cardiol . 2018;71:193-200.
8. "Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial". Lancet . 2022;399:1049-1058.
9. "Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction". Eur. Heart J . 2017;38:201-211.
10. "Biological substrate modification suppresses ventricular arrhythmias in a porcine model of chronic ischaemic cardiomyopathy". Eur Heart J . 2022;43:2139-2156.
11. "Augmenting canonical Wnt signalling in therapeutically inert cells converts them into therapeutically potent exosome factories". Nat Biomed Eng . 2019;3:695-705.
12. "Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice". Eur Heart J . 2021;42:3558-3571.
13. "Delayed repolarization underlies ventricular arrhythmias in rats with heart failure and preserved ejection fraction". Circulation . 2017;136:2037-2050.
14. "Ventricular arrhythmias underlie sudden death in rats with heart failure and preserved ejection fraction". Circ Arrhythm Electrophysiol . 2018;11:e006452.
15. "Reverse electrical remodeling in rats with heart failure and preserved ejection fraction". JCI Insight . 2018;3:e121123.
16. "Mechanisms of sinoatrial node dysfunction in heart failure with preserved ejection fraction". Circulation . 2022;145:45-60.
17. "Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction". Am J Physiol Heart Circ Physiol . 2022;323:5: H892-H903. https://doi.org/10.1152/ajpheart.00287.2022.
18. "Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction". Heart Rhythm . 2020;17:1025-1033.
19. "Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia". Nature . 2020;587:460-465.
20. "Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation". Circulation . 2018;138:2227-2242.
21. "Right atrial mechanisms of atrial fibrillation in a rat model of right heart disease". J Am Coll Cardiol . 2019;74:1332-1347.
22. "Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation". J Am Coll Cardiol Basic Trans Science . 2016;1:14-28.
23. "Frequency analysis in different types of paroxysmal atrial fibrillation". J Am Coll Cardiol . 2006;47:1401-1407.
24. "Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A". Circ Res . 2005;96:54-63.
25. "Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy". Circ Res . 2004;95:717-725.
26. "Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation". J Am Coll Cardiol . 2008;51:802-809.
27. "Role of inflammation in atrial fibrillation pathophysiology and management". Circ J . 2015;79:495-502.
28. "Association between oxidative stress and atrial fibrillation". Heart Rhythm . 2017;14:1849-1855.
29. "RNA fragment in extracellular vesicles confers cardioprotection via modulation of IL-10 expression and secretion". EMBO Mol Med . 2017;9:337-352.
30. "Chronic low-grade inflammation in heart failure with preserved ejection fraction". Aging Cell . 2021;20:e13453.
31. "A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation". J Am Coll Cardiol . 2013;62:263-271.
32. "Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins". J Am Coll Cardiol . 2016;68:2217-2228.
33. "Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation". J Am Coll Cardiol . 2020;76:1051-1064.
34. "Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort". Circulation . 1999;100:87-95.
35. "Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy". Circulation . 2020;141:4-6.
36. "Atrial remodeling and atrial fibrillation: mechanisms and implications". Circ Arrhythm Electrophysiol . 2008;1:62-73.
37. "Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap". Circulation . 2016;134:73-90.
38. "Fibroblasts rendered antifibrotic, antiapoptotic, and angiogenic by priming with cardiosphere-derived extracellular membrane vesicles". J Am Coll Cardiol . 2015;66:599-611.
39. "Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity". Circ Res . 2011;109:724-728.
40. "Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury". Stem Cell Res . 2013;10:301-312.
41. "Exosomes derived from human umbilical cord mesenchymal stem cells relieve acute myocardial ischemic injury". Stem Cells Int . 2015;2015:761643.
42. "Angiogenic mechanisms of human CD34+ stem cell exosomes in the repair of ischemic hindlimb". Circ Res . 2017;120:1466-1476.
43. "Cell-based therapy in cardiac regeneration: an overview". Circ Res . 2018;123:132-137.
44. "More than tiny sacks: stem cell exosomes as cell-free modality for cardiac repair". Circ Res . 2016;118:330-343.
45. "Communication by extracellular vesicles: where we are and where we need to go". Cell . 2016;164:1226-1232.
46. "Extracellular vesicles and the application of system biology and computational modeling in cardiac repair". Circ Res . 2018;123:188-204.
47. "Exosomes: fundamental biology and roles in cardiovascular physiology". Annu Rev Physiol . 2016;78:67-83.
48. "The evolution of the stem cell theory for heart failure". EBioMedicine . 2015;2:1871-1879.
49. "Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery". Adv Drug Deliv Rev . 2013;65:336-341.
50. "Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs". J Transl Med . 2011;9:47.
51. "Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure". Cardiovasc Res . 2004;63:236-244.